Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study

Abstract

Background:

Early restoration of blood flow of the infarct-related artery is associated with an improved outcome in patients with ST-elevation myocardial infarction (STEMI). Previous studies have shown a low mortality in patients with TIMI 3 flow before primary percutaneous coronary intervention (PCI). Most likely these patients had spontaneous recanalization of the infarct vessel and might constitute a low-risk subgroup. The purpose of the present analysis was to investigate whether TIMI 3 flow obtained with fibrinolysis before PCI is associated with a clinical outcome comparable to that in patients with spontaneous TIMI 3 flow.

Methods:

Patients with STEMI <6 hours enrolled in the ASSENT-4 PCI study were randomized to facilitated PCI with tenecteplase or primary PCI. For this analysis, patients were divided into three groups according to the TIMI flow of the infarct vessel before PCI: TIMI 0/1, TIMI 2, and TIMI 3.

Results:

From a total of 1617 patients, 861 had TIMI 0/1, 279 had TIMI 2, and 477 TIMI 3 flow. The rates of TIMI 3 flow after PCI were 84.6, 89.7, and 95.6%, respectively. Complete ST resolution was observed most often in the TIMI 3 flow group (47.5, 53.6, and 58.6%). The incidence of cardiogenic shock (6.2, 5.5, and 3.6%) and 90-day mortality (6.1, 4.7, and 4.0%) were lowest in the group with TIMI 3 patency before PCI, respectively. The rate of TIMI 3 flow before PCI was higher in the facilitated PCI group than in the primary PCI group (43.9 vs. 15.2%). The 90-day mortality in patients with TIMI 3 before PCI was identical in the facilitated and the primary PCI groups (14/353, 4.0% vs. 5/124, 4.0%).

Conclusion:

In this post-hoc analysis of ASSENT-4 PCI, TIMI grade 3 flow in the infarct-related artery before PCI, occurring either spontaneously or obtained by fibrinolysis, is associated with a higher TIMI patency after PCI, better improved ST resolution and a trend towards a favourable clinical outcome after 90 days.

Keywords

Facilitated PCI patency primary percutaneous coronary intervention ST-elevation myocardial infarction

Get full access to this article

View all access options for this article.

References

Simes

Topol

Holmes

Jr. . Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91: 1923–1928.

De Luca

Suryapranata

Ottervanger

. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109: 1223–1225.

Reimer

Vander Heide

Richard

. Reperfusion in acute myocardial infarction: effects of timing and modulating factors in experimental models. Am J Cardiol 1993; 72: 13G–21G.

Tarantini

Cacciavillani

Corbetti

. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol 2005; 46: 1229–1235.

Keeley

Boura

Grines

. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13–20.

Miedema

Newell

Duval

. Causes of delay and associated mortality in patients with ST-segment myocardial infarction. Circulation 2011; 124: 1636–1644.

Gersh

Stone

White

. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 2005; 293: 979–998.

Stone

Cox

Garcia

. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104: 636–641.

Brodie

Stuckey

Hansen

. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000; 85: 13–18.

10.

The ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction (ASSENT-4 PCI). Lancet 2006: 367: 569–578.

11.

TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 1985; 312: 932–936.

12.

Schröder

Zeymer

Wegscheider

.; for the HIT-4 trial group. Comparison of the predictive value of ST segment elevation resolution 90 and 180 minutes after start of streptokinase in acute myocardial infarction. A substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 Study. Eur Heart J 1999; 20: 1563–1571.

13.

Van

Werf

Bax

Betriu

. Management of acute myocardial infarction in patients presenting with pesistent ST-segment elevation. Eur Heart J 2008; 29: 2909–2945.

14.

De Luca

Gibson

Bellandi

. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation. An individual patients’ data meta-analysis. Heart 2008; 94: 1548–1558.

15.

Herrmann

Brodie

. FINESSE Investigators. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv 2009; 2: 917–924.

16.

Bainey

Wagner

. Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. Am Heart J 2008; 156; 156: 248–255.

17.

Heestermans

de Boer

van Werkum

JVV

. Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI. Protection for the negative impact of time delay. EuroIntervention 2011; 7: 442–448

18.

Zeymer

Arntz

H-R

Mark

. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention inacute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012; 101: 305–312.